William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on TransMedics Group. The associated price target remains the same with $148.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
William Plovanic has given his Buy rating due to a combination of factors pointing to robust underlying demand for TransMedics’ platform in early 2026. January UNOS transplant statistics and JetSpy flight data both indicate a healthy start to Q1, with record monthly flight hours for TMDX logistics and strong growth in total organ transplants, particularly in donation-after-circulatory-death procedures where the company holds clear market leadership.
Plovanic also highlights that liver, heart, and lung trends collectively support continued revenue expansion, reinforced by TMDX’s dominant position in DCD organs and favorable clinical and regulatory catalysts such as OCS ENHANCE and DENOVO. While acknowledging volatility in transplant volumes and some weakness in traditional brain-death donations, he believes current metrics and trial-driven adoption underpin his Q1/26 revenue forecasts and justify maintaining a positive, long-term stance on the shares.
In another report released on February 5, TD Cowen also reiterated a Buy rating on the stock with a $170.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.